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Abstract A crucial aspect of ligand-mediated receptor activa-
tion and shut-down is receptor internalization and degradation.
Here we compared the ubiquitylation of either wild type or a
K508A ‘kinase-dead’ mutant of ¢broblast growth factor recep-
tor 3 (FGFR3) with that of its naturally occurring overactive
mutants, G380R as in achondroplasia, or K650E involved in
thanatophoric dysplasia. Fibroblast growth factor receptors
ubiquitylation was found to be directly proportional to their
intrinsic tyrosine kinase activity, both of which could be blocked
using kinase inhibitors. Despite excessive ubiquitylation, both
overactive mutants failed to be e⁄ciently degraded, even when
challenged with ligand or overexpression of c-Cbl, a putative E3
ligase. We conclude that phosphorylation is essential for
FGFR3 ubiquitylation, but is not su⁄cient to induce downregu-
lation of its internalization resistant mutants. 2 2002 Pub-
lished by Elsevier Science B.V. on behalf of the Federation of
European Biochemical Societies.
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1. Introduction
Fibroblast growth factor receptor 3 (FGFR3) is one of four
distinct members of membrane spanning tyrosine kinases that
serve as high a⁄nity receptors for more than 20 di¡erent
¢broblast growth factors (FGFs) [1]. Binding of the FGF li-
gand in concert with a heparan sulfate [2] induces receptor
dimerization, trans-phosphorylation and activation followed
by receptor internalization and downregulation. These lead
to the controlled activation of speci¢c signal transduction
pathways and expression of FGF target genes, critically re-
quired during embryogenesis, tissue repair and angiogenesis
[3,4].
Mutations in FGF receptors 1, 2 and 3 are known to give
rise to a variety of inherited skeletal disorders [5,6]. Mutations
in FGFR3 are responsible for disorders predominantly of the
long bones, including achondroplasia (Ach), the most com-
mon form of human genetic dwar¢sm [7,8]. A N540K muta-
tion in the proximal tyrosine kinase domain of FGFR3 is
found in the milder disorder of hypochondroplasia [9], while
substitutions of a cysteine for one of the residues 248, 249, 370
or 371 in the extracellular domain, or a K650E mutation in
the kinase domain, give rise to the most severe and neonatal
lethal, thanatophoric dysplasia (TD) types, I and II, respec-
tively [10,11]. All these skeletal malformations represent auto-
somal dominant disorders characterized by disproportionately
short limbs and relative macrocephally.
The predominant molecular mechanism underlying the var-
ious chondrodysplasia syndromes is constitutive, ligand-inde-
pendent activation of the mutant receptors and their down-
stream signaling [12]. For example, TDI results from covalent
disul¢de linked receptor^dimers, while TDII results most
often from direct activating mutations in the kinase domain
of FGFR3, both of which can lead to ligand-independent,
constitutive receptor autophosphorylation [10,13]. Recently
we have found that the Ach mutation G380R uncouples li-
gand-mediated receptor activation from its downregulation,
leading to excessive receptor accumulation and inappropriate
FGF-mediated signaling [14]. The implication of this ¢nding
is that signal termination via receptor degradation is an essen-
tial component of FGF signal transduction, similarly to other
tyrosine-kinase receptors [15]. However, questions regarding
the mechanism and the reasons for the resistance of these
FGFR3 mutants to downregulation have remained open.
Among the most likely candidate mechanisms of FGFR3
breakdown is via the proteosome, after tagging with ubiquitin.
The 76 amino acid polypeptide, ubiquitin, is attached onto
proteins by the sequential action of the enzymes E1, E2 and
E3. The E1 enzyme ¢rst activates ubiquitin in an ATP-depen-
dent manner, ubiquitin is then transferred to the active site of
an ubiquitin-conjugating enzyme (E2) and then to the active
site of an ubiquitin-protein ligase (E3) [16]. In the last reac-
tion, catalyzed either by E2 with the help of E3, or directly by
E3, an isopeptide bond is formed between the C-terminal gly-
cine of ubiquitin, and the O-amino group of a lysine residue on
the target protein. The generation of multiubiquitin chains is
often mediated by the repeated attachment of ubiquitin onto
Lys48 of another ubiquitin or of a growing ubiquitin chain.
The E3 enzymes therefore perform the important task of rec-
ognizing proteins destined for degradation by the proteosome
[17]. It is now widely accepted that Cbl functions as a negative
regulator of receptor tyrosine kinases (RTKs), possibly by
acting as an E3 ligase as demonstrated by Cbl-induced ubqui-
tylation [18].
In the case of plasma membrane proteins, the function of
ubiquitylation may extend beyond just tagging for degrada-
tion. In yeast, it serves to trigger the internalization of plasma
membrane proteins via the endocytic pathway [19], which
leads to their subsequent degradation in the vacuole. In at
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least one case, that of the growth hormone receptor (GHR),
ubiquitylation is required for internalization of the receptor,
however, it is unlikely that ubiquitylation is the sole trigger
for internalization [20,21].
So far only one study of FGFR ubiquitylation has been
reported, in which it was shown that FGFR1 ubiquitylation
is ligand-dependent, although to a lesser extent than for other
members of the tyrosine kinase receptors super-family [22]. In
the present study we have analyzed the ubiquitylation patterns
of FGFR3 and its naturally occurring mutants, their depen-
dence on kinase activity and the relationship between ubiqui-
tylation and degradation of these receptors.
2. Materials and methods
2.1. Cell lines
Non-transformed rat chondrocytes derived from fetal calvaria (RCJ
3.1C5.18), a generous gift from Dr. J. Aubin [23], and human embry-
onal kidney cells expressing large T-antigen (293T). The cells were
cultured in Dulbecco’s modi¢ed Eagle’s medium containing 10% fetal
calf serum.
2.2. Expression of wild type (WT) and mutant human FGFR3
Transfections : cDNAs of the WT FGFR3, Ach (G380R), TDII
(K650E) and kinase-dead (KD) (K508A) mutants in pcDNA3 expres-
sion vector (Invitrogen) and ubiquitin^HA (ubiquitin^hemagglutinin)
and Cbl^HA (Cbl^hemagglutinin) were transfected into 293T cells by
the calcium phosphate method. Infections : Retroviruses of the
FGFR3 and the Ach mutant were produced in 293T cells by co-trans-
fection of these cDNAs in a pLXSN vector with a Psi helper phage.
Collection of virus-containing medium started 30 h after transfection.
Medium was collected ¢ve times at 8 h intervals. The infected medium
was ¢ltered and kept at 380‡C for further use. The infections were
performed by incubating RCJ cells with the virus-enriched medium
and 8 Wg/ml of polybrene for 6 h followed by selection in G418 (0.5
Wg/ml). Positive pools were screened for FGFR3 expression by SDS^
PAGE and Western blots.
2.3. Immunoprecipitation and immunoblotting
Cells were lysed in lysis bu¡er (50 mM Tris/HCl, pH 8.0, 150 mM
NaCl, 1 mM MgCl2, 0.1 mM ZnCl2, 0.5% Nonidet P-40, 1 mg/ml
approtinin, 1 mg/ml leupeptin, 2 mM phenylmethylsulfonyl £uoride)
and clari¢ed by centrifugation at 12 000Ug for 15 min. The lysates
were subjected to immunoprecipitation for 16 h at 4‡C with anti-
FGFR3 C-terminus antibody (Santa Cruz, CA, USA); and analyzed
by 6% SDS^PAGE and Western blots. Monoclonal anti-HA antibod-
ies were a generous gift from Dr. Yaov Henis, Tel Aviv University;
antibodies to ubiquitin were from Sigma. Protein bands were visual-
ized using secondary antibodies coupled to horseradish peroxidase
and the ECL kit (Amersham) according to the manufacturer’s instruc-
tions. Densitometry was done using a Model GS-690 Imaging Densi-
tometer (Bio-Rad).
3. Results
3.1. Ubiquitylation of FGFR3 and its mutants
Ubiquitylation of FGFR3 was analyzed by co-expressing
the WT receptor or its mutants together with an ubiquitin^
HA fusion protein and analyzing their associated HA-tag
after 20, 48 and 90 h (Fig. 1). The expression levels of the
WT and Ach FGFR3 reached a peak at 48 h and declined by
90 h, while the TDII mutant levels remained relatively un-
changed up to 90 h (Fig. 1, top panel). The ubiquitylation
pattern of the WT receptors, as detected by the HA-tag,
also peaked at 48 h and thereafter declined in parallel with
the receptor protein levels (Fig. 1, bottom panel). In contrast,
Fig. 1. Time-dependent expression and ubiquitylation of WT, Ach (G380R) and TDII (K650E) FGFR3. 293T cells were transiently transfected
with the WT, Ach and TDII mutant receptors, together with the ubiquitin^HA construct. After the indicated time periods the cells were lysed,
immunoprecipitated with anti-FGFR3 C-terminus antibodies and probed on an immunoblot with antibodies to either the kinase domain of
FGFR3 (KFGFR3) or anti-HA (KHA^ubiq). NT, transfected only with HA^ubiquitin (without FGFR3).
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the Ach and TDII mutant receptors remained highly ubiqui-
tylated even at 90 h. Some ubiquitylation was also detected
in non-transfected cells and is attributable to endogenous
FGFR3 expression in 293T cells. The ubiquitylated proteins,
corresponding to intact receptors and their degradation prod-
ucts bearing ubiquitin chains of di¡erent lengths, typically
appear as ladders in SDS^PAGE due to their anomalous mo-
bility.
3.2. Ubiquitylation of FGFR3 correlates with its kinase activity
We asked whether the high ubiquitylation of the two over-
active mutant receptors was related to their increased tyrosine
kinase activity. To this end, 293T cells expressing variously
active mutants of FGFR3 together with the ubiquitin^HA
construct were analyzed for expression, tyrosine phosphoryla-
tion as well as FGFR3 ubiquitylation (Fig. 2). The Ach mu-
tant was more ubiquitylated than the WT, but less than the
TDII mutant, while the KD K508A mutant failed to undergo
phosphorylation and did not appear to be ubiquitylated at all
(Fig. 2, bottom panel). The relative ubiquitylation levels fol-
lowed the order TDIIsAchsWTsKD and paralleled the
observed tyrosine phosphorylation levels (Fig. 2, middle pan-
el). The detected phosphorylation levels are also in agreement
with the expected relative activity of these receptors and the
severity of the corresponding disorders [24,25]. It is notable
that all these receptors showed tyrosine phosphorylation even
though the cells were not stimulated with exogenous FGF.
This activity could conceivably result from the high levels of
receptor expression in the cells that might promote their spon-
taneous dimerization and phosphorylation, or due to some
FGFs secreted into the medium by the same cells [26].
The addition of saturating amounts of FGF9 to produce
maximal FGFR3 stimulation caused only a mild increase in
the ubiquitylation of the WT receptor within 30 min when
taking into account the corresponding receptor levels (Fig.
3A). Furthermore, 30 min of FGF9 exposure did not notice-
ably change the ubiquitylation levels of the Ach or TDII
mutants (Fig. 3A, lower panel). Since the e¡ect of the ligand
after 30 min was only moderate, we further studied longer
activation periods enabling processes which require new pro-
tein synthesis. Six hours of FGF9 exposure indeed produced a
more notable increase in the ubiquitylation of WT and Ach
receptors (Fig. 3B). The TDII mutant increase in ubiquityla-
tion is less pronounced, due to its very high constitutive basal
kinase activity. An inhibitor of FGFR3 tyrosine kinase, SU
5402 [27], signi¢cantly inhibited the ubiquitylation of all of
the receptor types (Fig. 3B). Taken together, these results
indicate a good correlation between RTK activity and ubiq-
uitylation level, nevertheless only after prolonged activation.
To test the possibility that c-Cbl, the E3 ubiquitin ligase of
the EGF receptor, may also be associated with FGFR3 or its
mutants, we performed co-transfections of FGFR3 cDNA
with a c-Cbl^HA construct. Following immunoprecipitation
and Western blot analysis, no direct association between these
two proteins could be observed (Fig. 4). Furthermore, over-
expression of c-Cbl did not a¡ect the expression of FGFR3 or
its ubiquitylation, in contrast to similar experiments reported
for the EGF receptor [28]. Interestingly, a correlation was
found between the expression of c-Cbl and the activity of
FGFR3. Expression of the overactive mutant receptors
yielded higher levels of c-Cbl, with the highest level of c-Cbl
detected in cells expressing the TDII mutant (not shown).
3.3. The degradation pathway of FGFR3 ^ proteosomes versus
lysosomes
A number of plasma membrane proteins that are ubiquity-
lated appear to be degraded through both the proteosomal
and lysosomal pathways [29]. In an attempt to identify the
preferred degradation pathway of FGFR3 following its acti-
vation, we used chloroquine and MG-132, inhibitors of lyso-
somal and proteosomal degradation, respectively. In these ex-
periments (Fig. 5) we employed the RCJ chondrocyte cell line
model [30]. RCJ cells expressing either WT or the Ach mutant
FGFR3 were exposed to FGF9 for 1 h, in the presence of
cycloheximide, to block protein synthesis, with or without the
addition of chloroquine or MG-132. As expected, addition of
FGF9 caused a dramatic decrease in the level of the WT
receptor (Fig. 5, top panel). Both chloroquine and MG-132
prevented most of this e¡ect, indicating that degradation of
FGFR3 involves both the proteosomal and lysosomal path-
ways. FGF9-induced degradation of the Ach mutant FGFR3
was, as expected, less marked than for the WT, but was also
prevented by both chloroquine and MG-132. The total ubiq-
uitylation of these receptors, analyzed with anti-ubiquitin
antibodies (Fig. 5, bottom panel), appeared unchanged fol-
lowing FGF9 stimulation. However, when compared to the
total receptor protein level, which decreased after FGF9 ex-
posure, the stoichiometric ratio of ubiquitin/FGFR3 actually
increased, particularly in the case of the WT protein. This
Fig. 2. Tyrosine phosphorylation and ubiquitylation of WT and mu-
tant FGFR3. 293T cells were transiently co-transfected with the
WT, G380R Ach, K650E TDII and K508A KD mutant receptors,
together with the ubiquitin^HA construct, for 48 h. The transfected
cells were lysed, immunoprecipitated with anti-FGFR3 C-terminus
antibodies and probed on an immunoblot with antibodies to the ki-
nase domain of FGFR3 (KFGFR3, top), anti-phosphotyrosine
(KPY, middle) or anti-HA (KHA^ubiq, bottom).
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con¢rms the observation of ligand-activated enhancement of
receptor ubiquitylation. Blocking receptor degradation by
chloroquine or MG-132 caused an accumulation of both
WT and Ach mutant ubiquitylated receptors (Fig. 5, bottom
panel).
4. Discussion
We have previously found that a naturally occurring muta-
tion in FGFR3, in which glycine 380 is substituted by arginine
(G380R) in the trans-membrane domain of the receptor, re-
sults in a speci¢c defect in internalization, leading to stabili-
zation and accumulation of the mutant receptor at the cell
surface. The direct consequence of this impaired internaliza-
tion is uncontrolled and prolonged ligand-dependent activa-
tion of this receptor in chondrocytes [14]. This is thought to
lead to the observed inhibition of chondrocyte maturation and
terminal di¡erentiation which is the underlying cause of the
most common form of human dwar¢sm, Ach. The aim of this
work was to investigate the basis of the defective downregu-
lation of this and other mutant FGF receptors.
The primary focus in this study was on FGFR3 ubiquity-
lation, since this process is known to be directly involved in
the internalization of membrane proteins in yeast and mam-
malian cells [31] as well as in the downregulation of various
membrane receptors, transporters and channels [15]. In most
cases, ubiquitylation of these plasma membrane proteins leads
to their internalization followed by targeting to the lysosome
Fig. 3. The e¡ect of FGF9 stimulation and of a tyrosine kinase inhibitor on ubiquitylation of WT and mutant FGFR3. A: 293T cells were
transiently transfected with the WT, Ach or TDII receptors, either without or together with the ubiquitin^HA construct (HA^ubiq). Forty-eight
hours later and following incubation with or without FGF9 for another 30 min, the cells were lysed, immunoprecipitated with anti-FGFR3
C-terminus antibodies and probed on an immunoblot with antibodies to either the kinase domain of FGFR3 (KFGFR3) or anti-HA (KHA^
ubiq). B: 293T cells co-expressing FGFR3 and ubiquitin^HA for 48 h were incubated with or without FGF9 for 6 h in the absence and pres-
ence of the kinase inhibitor SU 5402 and analyzed for ubiquitin^HA (KHA^ubiq) as above.
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(or vacuole in yeast) for degradation [29]. At least eight plas-
ma membrane proteins in animal cells have been shown to be
ubiquitylated at the cell surface. Among these are the GHR,
the T cell receptor and several growth factor RTKs, such as
the epidermal growth factor receptor, platelet-derived growth
factor receptor (PDGFR) the colony stimulating factor-1 re-
ceptor (CSF1) [19,32^34] as well as FGFR1 [22].
Ligation of ubiquitin to the protein and tagging it to deg-
radation in the proteosome system was suggested to occur via
two di¡erent pathways. Ubiquitylation may serve as a signal
for internalization, which is followed by protein degradation,
implying that membrane proteins undergo ubiquitylation even
before entering the early endosome [35]. The second hypoth-
esis suggested ¢rst for the EGF system supports a concept in
which receptor internalization does not require ubiquitin but
occurs by recruitment of various additional components that
form the clathrin-coated vesicle. Uncoating of the vesicle then
serves to form the early endosome, in which the receptors are
sorted either for degradation by ubiquitin conjugation (medi-
ated by c-Cbl), or for recycling back to the membrane by
another tag (mediated by v-Cbl) [36].
Ubiquitylation of FGFR1 [22], was shown to be ligand-de-
pendent, although to a lesser extent than other members of
the RTK super-family. We have con¢rmed this for FGFR3 by
showing FGF9-induced ubiquitylation of both the WT and
Fig. 4. Co-immunoprecipitation of FGFR3 and c-Cbl^HA. 293T
cells were transiently co-transfected with the WT FGFR3 and
c-Cbl^HA. Two days later and following incubation with FGF9
(50 ng/ml) for 30 min, the cells were lysed, and immunoprecipitated
(IP) with either anti-FGFR3 antibodies (KFGFR3) or anti-HA
(KHA^Cbl). The lysates and the IPs were probed on an immunoblot
with antibodies to either the kinase domain of FGFR3 (KFGFR3)
or anti-HA (KHA^Cbl).
Fig. 5. E¡ect of proteosome and lysosome inhibitors on FGFR3 degradation in chondrocytes. RCJ cells expressing the WT or the Ach mutant
FGFR3 were incubated with or without FGF9 (50 ng/ml) for 1 h, in the absence and presence of MG-132 (50 WM) or chloroquine (500 WM),
as indicated. Protein synthesis was blocked by co-incubation with 10 Wg/ml of cycloheximide (Chx). Cell lysates were immunoprecipitated with
anti-FGFR3 antibodies and probed on an immunoblot with antibodies against the kinase domain of FGFR3 (upper panel, ‘KFGFR3’) or
monoclonal antibodies against ubiquitin (lower panel, ‘K-ubiq’).
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Ach mutant receptor forms. In addition, we have shown that
the ubiquitylation levels of FGFR3 are dependent on its ty-
rosine kinase activity by several means: (i) low or non-detect-
able levels of ubiquitylation of the KD mutant receptor; (ii)
blocking ubiquitylation upon treatment with kinase inhibitor;
and (iii) proportionally high ubiquitylation levels are found in
the case of the overactive Ach and TDII mutants. We con-
clude that tyrosine phosphorylation of FGFR3 is essential
and acts as a trigger for its ubiquitylation. This is in line
with proposals that phosphorylation and the exposure of the
phosphorylation site facilitate the access of the ubiquitin con-
jugation machinery to the receptor [20,29,35]. However, tyro-
sine phosphorylation of FGFR3 by itself is not su⁄cient to
induce ubiquitylation, as concluded from the duration re-
quired to induce the process. Only long exposure (6 h or
more) of the cells to FGF induced ligand-dependent ubiqui-
tylation, suggesting that the activation of the receptor pro-
motes the transcription of one or more proteins required for
its ubiquitylation, as was shown for P53/MDM2 [37]. Thirty
minutes of exposure of cells to FGF, although is su⁄cient to
induce phosphorylation, downstream signaling and downregu-
lation of the receptor, is yet not enough to accomplish signi¢-
cant ubiquitylation of this receptor.
In the case of WT FGFR3, ubiquitylation induced by
FGF9 or by high levels of ubiquitin expression leads to its
downregulation, presumably via degradation. However, this
does not hold for the Ach or TDII mutants, whose levels
are not noticeably altered in spite of their robust ubiquityla-
tion, which is commensurate with their activity. Therefore, the
failure of these mutant receptors to be downregulated cannot
be attributed to a defect in ubiquitylation. Also, when these
results are considered together with the ine⁄cient internaliza-
tion of the Ach FGFR3 mutant [14], they indicate that, at
least in this case, ubiquitylation may occur independently of
internalization.
The ubiquitylation process involves the activities of E1, E2
and E3. In the latest reaction by an E3, ubiquitin is attached
to lysine residues on the protein and later is elongated by
repeated attachment of ubiquitin to form multiubiquitin
chains. One such E3 for membrane-associated receptors is c-
Cbl, a tyrosine kinase regulator for EGF, PDGF and CSF1
receptors [30,38^40]. In a most recent study it was demon-
strated that FGFR1 signaling is attenuated via an indirect
association of Cbl with FRS2K [41]. This was suggested to
occur by the formation of a ternary-complex whereby Grb2
is bound to FRSK by means of its SH2 domain and to Cbl by
means to its two SH3 domains. We could not observe any
direct association between FGFR3 and c-Cbl, most likely due
to the multiple protein and low a⁄nity nature of these inter-
actions. This is in contrast to other RTKs such as EGF, CSF1
or PDGF receptors which directly bind Cbl [18,38,39]. While
overexpression of c-Cbl did not, in our hands, a¡ect the ex-
pression of FGFR3 or its ubiquitylation (not shown), the
observation that overactive mutants, such as the K650E
FGFR3, induce high expression levels of c-Cbl do suggest
for some feedback interaction between c-Cbl and the activity
of FGFR3.
The degradation of several mammalian receptors that are
known to undergo ligand-stimulated ubiquitylation appears to
be impaired by inhibitors of proteosome-mediated breakdown
of ubiquitylated proteins, as well as by agents that block ly-
sosomal degradation. This has been reported for the PDGFR
and the met tyrosine kinase receptor [33,42]. It is possible that
a part of these receptors is degraded by the proteosome while
another fraction is degraded in the lysosome [43]. Yet another
possibility is that proteosome-dependent degradation of a
protein other than the receptor might be required for e⁄cient
targeting and transport to the lysosome [44]. The degradation
of FGFR3 seems to involve both the proteosomal and lyso-
somal pathways, since the proteosomal and lysosomal inhib-
itors MG-132 and chloroquine blocked ligand-dependent deg-
radation of the WT receptor. These ¢ndings were less obvious
for the Ach mutant receptor whose degradation was less pro-
nounced. Nonetheless, the fact that inhibition of WT and Ach
receptor breakdown causes accumulation of receptor-associ-
ated ubiquitin in both FGFR3 forms to above control levels
indicates that ubiquitylated receptors are continuously re-
moved by degradation and that the degradation pathways
of the WT and Ach FGFR3s are similar if not identical.
The ubiquitylation mechanism comprises an extra control
level on the activity and expression of receptors on the cell
surface, which is particularly important for FGFR3 activity in
the epiphyseal growth plates of long bones. Since ubiquityla-
tion in itself is evidently necessary, but not su⁄cient for nor-
mal internalization and degradation of FGFR3, it is likely
that other mechanisms may be involved. Ligand-activated
FGFR3 interacted with a multitude of signaling molecules
and adaptor proteins, including among others, Grb, Jak,
PI3K, Src and SNT/FRS2 [45,46]. One possibility to be inves-
tigated is that human pathology associated mutant receptors
fail to interact with one or more of these proteins responsible
also for their internalization.
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